Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies. (2013). Radiology and Oncology, 47(1). https://radioloncol.com/index.php/ro/article/view/728